PIRS (Pieris Pharmaceuticals) Earnings per share growth rate in current year
Pieris Pharmaceuticals (PIRS) develops Anticalin protein therapeutics to combat asthma and cancer. Outsourcing production and testing ensures structural flexibility, which is reflected in the relative EPS YoY trend, where this metric equals -70.20. Management is currently cutting secondary projects to preserve capital and seek partners in an effort to stabilize earnings per share dynamics.
Financial and market metric breakdowns for Pieris Pharma (PIRS)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt and liquidity details:
Total Debt to Capital Coefficient Pieris Pharmaceuticals|PIRS - Long-Term Debt to Capital|Current Liabilities to Capital Pieris Pharmaceuticals Inc|PIRS - Company Debts|Debt to Net Assets Ratio Pieris Pharmaceuticals|PIRS - Company Long-Term Debts|Short-Term Debt Volume Pieris Pharmaceuticals|Interim Coverage Ratio pieris.com
- net income and valuation multiples indicators:
PIRS - Net Income|Expected Net Income Pieris Pharmaceuticals|PIRS - Price to Earnings Ratio|Price to Expected Earnings Ratio Pieris Pharmaceuticals|PIRS - PEG Multiple|Business Value to Operating Income Before Depreciation Pieris Pharmaceuticals|PIRS - Operating profit EBITDA|Net earnings per share (EPS TTM) Pieris Pharmaceuticals|PIRS - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months pieris.com|PIRS - Earnings per share growth in current year|Expected earnings per share growth for next year Pieris Pharmaceuticals
- revenue and sales proceeds data:
Basic company analysis:Pieris (PIRS)
The development of innovative therapies by Pieris Pharmaceuticals (PIRS) is complicated by global geopolitical fragmentation, which disrupts component logistics and the execution of global clinical trials. The relative annual growth in net income per share quantifies the business's ability to generate earnings per share compared to the previous period, highlighting the effectiveness of cost management. The trend of this metric allows investors to assess the resilience of the business model to external shocks and the risk of falling into a value trap.
Direct competitors
Earnings per share growth rate in current year Haleon Corp (HLN)|KVUE (Kenvue Inc) - Earnings growth in current year|Earnings per share growth rate in current year veronapharma.com VRNA|Earnings per share growth in current year Jyong Biotech (MENS)|LGND (Ligand Pharmaceuticals Incorporated) - Earnings per share increase in current year|Earnings growth in current year AMRX (Amneal Pharmaceuticals, Inc.)|PRGO (Perrigo Company) - Earnings per share trend in current year|ALVO - Earnings per share growth in current year|Expected net earnings per share growth this year liquidia.com LQDA|Galapagos (GLPG) - Earnings per share growth in current year|ANIP - Expected net earnings per share growth this year|Earnings per share growth in current year MannKind Corporation|AMPH: Earnings per share increase in current year|Earnings per share growth in current year Pacira BioSciences (PCRX)|SPRY: Earnings per share trend in current year|Theravance Biopharma, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year AQST (Aquestive Therapeutics, Inc.)|SCPH - Earnings per share growth in current year|Expected net earnings per share growth this year tectonictx.com TECX|TNXP: Earnings growth in current year|Earnings per share growth this year SXTC|Net earnings per share growth this year EPRX|BioHarvest (BHST) - Expected net earnings per share growth this year|Earnings growth in current year EXOZ|Earnings growth in current year Oramed (ORMP)|Entera Bio Ltd. - Net earnings per share growth this year|ipatherapeutics.com (HYFT) - Earnings per share growth rate in current year|ABVC - Earnings per share growth in current year|Earnings per share trend in current year CPIX|QNTM: Earnings growth in current year|FGEN - Expected net earnings per share growth this year|TELO (Telomir Pharmaceuticals Corp) - Earnings growth in current year|RANI (Rani Therapeutics) - Net earnings per one share growth for the current year|Earnings per share growth in current year Synergy CHC Corp. (SNYR)|RLYB (Rallybio) - Earnings per share increase in current year|Earnings per share growth in current year lexariabioscience.com LEXX|Earnings growth in current year Pulmatrix Corporation PULM|PTHL - Earnings per share growth in current year|Expected net earnings per share growth this year Aptorum Group Ltd APM|LYRA (Lyra Therapeutics) - Net earnings per share growth this year|IBO - Expected net earnings per share growth this year|Earnings per share growth in current year TNF Pharmaceuticals, Inc.|Net earnings per share growth this year cbdMD, Inc. (YCBD)|Earnings per share growth in current year PainReform Limited (PRFX)|Net earnings per share growth this year Altamira Therapeutics Ltd CYTO|Earnings growth in current year LIPO (lipella.com)|Earnings per share increase in current year OPTN|Procaps Group Corp - Earnings growth in current year|Expected net earnings per share growth this year Petros Pharma PTPI|Qilian International Holding Group Limited (QLI) - Earnings per share growth in current year|ACELYRIN (SLRN) - Earnings growth in current year|Earnings per share growth in current year TFF Pharmaceuticals
